Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated ps ...

and major depressive disorder (MDD),” said Rob Barrow, Chief Executive Officer of MindMed. “Gregg’s deep expertise in leading the regulatory approvals of transformative psychiatric drugs—demonstrated ...

While both of those medical issues are debilitating, there are no affordable and effective treatments, which creates an urgent medical need for Cardiol Therapeutics’ CardioRx™ – an oral solution in ...